Document is current

Article History

Received: 24 January 2022

Accepted: 15 November 2022

First Online: 29 November 2022

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki with ethical approval obtained from the Danish Ethical Committee of the Capital Region of Denmark (J.no.: H-18024568), and the General Data Protection Regulation approved by the Capital Region of Denmark (J.no.: BFH-2015-043). All patients provided written informed consent before inclusion. The Parker Institute’s PsA patient cohort study was registered at ExternalRef removed (NCT02572700). A pre-specified protocol is publicly available at the Parker Institute’s website (ExternalRef removed).

: Marie Skougaard has received research funding from, the Danish Rheumatism Association, the Danish National Psoriasis Foundation, and Pfizer that is besides the funding already disclosed under fundingSisse B. Ditlev has no conflicts of interestZara R. Stisen has no conflicts of interestLaura C. Coates has received honoraria, grant/research support or consulting fees from AbbVie, Amgen, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Sun Pharma, and UCB; and is a member of a speakers’ bureau for AbbVie, Amgen, Biogen, BMS, Celgene, Eli Lilly, Janssen, Medac, Novartis, Pfizer, Sun Pharma, and UCBKaren Ellegaard has no conflicts of interestLars Erik Kristensen has received fees for speaking and consultancy from AbbVie, Amgen, Biogen, Bristol Myers Squibb, Eli Lilly, Gilead, Janssen, MSD, Novartis, Pfizer, and UCB. And IIT grants from Biogen, Eli Lilly, Janssen, Novartis, Pfizer, and UCB.